Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer. [electronic resource]
Producer: 20151204Description: 143-50 p. digitalISSN:- 1549-490X
- Adult
- Aged
- Albumins -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Deoxycytidine -- administration & dosage
- Disease-Free Survival
- Female
- Humans
- Liver Neoplasms -- drug therapy
- Male
- Middle Aged
- Paclitaxel -- administration & dosage
- Pancreatic Neoplasms -- drug therapy
- Prognosis
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.